Skip to main content
Explore URMC

Rachael B. Turner, M.D., Ph.D.

Contact Information

Phone Numbers

Appointment: (585) 442-8020

Administrative: (585) 442-8020

Office: (585) 442-8020

Fax: (585) 442-8039

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Obstetrics & Gynecology


Dr. Rachael Turner received her medical degree and her PhD from the University at Buffalo School of Medicine and Biomedical Sciences in 2013. Dr. Turner then completed her Internal Medicine Residency and Medical Oncology Fellowship at the University of Rochester Medical Center in 2015 and 2018, respectively. She is currently pursuing a Research Fellowship at the University of Rochester Medical Center. Dr. Turner is certified by the American Board of Internal Medicine.

Dr. Turner's special interests are women's cancers, including fallopian, ovarian, uterine and cervical. She is also interested in immune therapies for cancer. Dr. Turner is committed to providing personalized cancer care with compassion and dedication.

During her free time, Dr. Turner enjoys spending time with her husband and sons, running and hiking.



MD | SUNY at Buffalo-School of Medicine & Biomedical Sciences (USA)

Post-doctoral Training & Residency

07/01/2015 - 07/19/2018
Fellowship in Hematology & Oncology at University of Rochester Medical Center

07/01/2014 - 06/30/2015
Residency in Internal Medicine at University of Rochester Medical Center

07/01/2013 - 06/30/2014
Internship in Internal Medicine at University of Rochester Medical Center

VIEW ALL expand_more


2020 - 2021
Internal Medicine Department Faculty Pilot Award
Sponsor: University of Rochester
Location: Rochester, NY

2019 - 2020
Technology Development Fund Grant
Sponsor: University of Rochester
Location: Rochester, NY

2019 - 2020
W.G Stuber Research Award
Sponsor: University of Rochester
Location: Rochester, NY

Wilmot Fellowship Award
Sponsor: Wilmot Cancer Institute
Location: Rochester, NY

Conquer Cancer Foundation/Women who Conquer Cancer- Young Investigator Award
Sponsor: Bristol-Myers Squibb
Location: ASCO

Best Overall Poster Presentation for HE4 in Ovarian Cancer Immune Suppression Poster Presentation
Sponsor: James P. Wilmot Cancer Institute
Location: Rochester, NY

Harold Brody Award for Translational Research
Sponsor: University of Buffalo
Location: Buffalo, NY

Honorable Mention for poster presentation on Chronic Chemoimmunotherapy etc..
Sponsor: Buffalo Immunology
Location: Buffalo, NY

2009 - 2011
Breast Cancer Pre-doctoral Traineeship Award
Sponsor: Department of Defense

Guy A. Bailey Outstanding Senior Award
Sponsor: SUNY Geneseo
Location: Geneseo, NY

Phi Beta Kappa National Honor Society

Tri-Beta Honor Society

VIEW ALL expand_more

Clinical Trials

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

Lead Researcher: Rachael B Turner

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

View Study Details


Journal Articles

Rowswell-Turner R; Singh R; Urh A; Yano N; Kim K; Khazan K; Pandita, R; Sivagnanalingam U; Hovanesian V; James N; Ribeiro J; Kadambi S; Linehan D; Moore R. "HE4 Overexpression by ovarian cancer promotes a suppressive tumor immune microenvironment and enhanced tumor and macrophage PD-L1 expression. Published online April 26,2021:" . J Immunol. 2021; .

Kim KK; Singh RK; Khazan N; Kodza A; Singh NA; Jones A; Sivagnanalingam U; Towner M; Itamochi H; Turner, R; Moore RG. "Development of Potent Forchlorfenurone Analogs and Their Cytotoxic Effect in Cancer Cell Lines." Sci Rep. 2020; 10(1): 3241.

Kim KK; Turner R; Khazan N; Kodza A; Jones A; Singh RK; Moore RG. "Role of trypsin and protease-active receptor-2 in ovarian cancer." PLOS One. 2020; 15(5): e0232253.